



**AWTTC**

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfar

## **The New Treatment Fund**

**Medicines Recommended by NICE and AWMSG:  
Health Board Formulary Status  
(From 1 January 2019 to 31 December 2019)**

## **BACKGROUND**

The Welsh Government launched the New Treatment Fund in January 2017. The fund provides an additional £16 million annually for health boards and trusts in Wales to support the faster introduction of new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of the publication of the decision. For NICE recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For AWMSG recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60 day timescale may be delayed because a Commercial Access Agreement (CAA) has not yet been agreed. In such circumstances this is indicated within the report. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, *The New Treatment Fund – Access to medicines recommended by NICE and AWMSG* (WHC [2017] 001).

A health board formulary is an official list of medicines which may be prescribed within the health board to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended between 1<sup>st</sup> January 2019 and 31<sup>st</sup> October 2019. All data in this report is as of 31<sup>st</sup> December 2019.

## **SOURCE OF INFORMATION**

Across Wales, the health boards use the online “Inform” formulary software programme provided and maintained by the NHS Wales Informatics Service (NWIS). Velindre NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This report has been compiled through a combination of an analysis of health board formularies and the submission of data and additional information from Chief Pharmacists.

**Table 1. Formulary status and time elapsed since latest AWMMSG/NICE recommendation for New Treatment Fund medicines (31 December 2019)**

| Appraisal Approval Date | CAA Available Date <sup>v</sup> | AWMSG or NICE ref | Medicine Name                               | Abbreviated Indication                      | Health Board formulary status <sup>^#</sup> |     |     |     |           |       |    |
|-------------------------|---------------------------------|-------------------|---|---|---|-----|-----|-----|-----------|-------|----|
|                         |                                 |                   |   |   | Aneurin Bevan                               | BCU | C&V | CTM | Hywel Dda | Powys | SB |
| 04/01/19                |                                 | ID1129 (TA565)    | Benralizumab                                | Asthma                                      | 6   | 18  | 34  | 20  | 34        | 40    | 0  |
| 17/01/19                |                                 | ID1227 (TA563)    | Abemaciclib                                 | Breast cancer                               | 11  | 8   | 49  | 7   | 21        | 27    | 0  |
| 18/01/19                |                                 | ID1097 (TA561)    | Venetoclax                                  | Leukaemia                                   | 7   | 7   | 48  | 10  | 20        | 26    | 0  |
| 18/01/19                |                                 | ID923 (TA562)     | Encorafenib                                 | Melanoma                                    | 3   | 4   | 48  | 6   | 20        | 26    | 0  |
| 18/01/19                |                                 | ID923 (TA562)     | Binimetinib                                 | Melanoma                                    | 3   | 4   | 48  | 6   | 20        | 26    | 0  |
| 15/02/19                |                                 | ID1192 (TA569)    | Pertuzumab                                  | Breast cancer                               | 3   | 7   | 48  | 3   | 21        | 32    | 4  |
| 15/02/19                |                                 | ID1328 (TA571)    | Brigatinib                                  | Lung cancer                                 | 5   | 7   | 48  | 7   | 21        | 32    | 0  |
| 21/02/19                |                                 | ID1158 (TA572)    | Ertugliflozin                               | Diabetes                                    | 7   | 14  | 42  | 11  | 15        | 26    | 0  |
| 05/03/19                |                                 | 3103              | Romiplostim                                 | Chronic idiopathic thrombocytopenic purpura | 6   | 8   | 30  | 6   | 3         | 14    | 0  |
| 05/03/19                |                                 | 2908              | Ciclosporin                                 | Conjunctivitis                              | 6   | 8   | 30  | 6   | 3         | 14    | 0  |
| 08/03/19                |                                 | ID1232 (TA574)    | Certolizumab                                | Psoriasis                                   | 3   | 5   | 27  | 3   | 0         | 11    | 0  |
| 08/03/19                |                                 | ID1060 (TA575)    | Tildrakizumab                               | Psoriasis                                   | 3   | 5   | 27  | 3   | 7         | 11    | 0  |
| 12/03/19                | 25/04/19                        | ID974 (TA573)     | Daratumumab                                 | Multiple myeloma                            | 1   | 7   | 42  | 105 | 20        | 6     | 0  |
| 21/03/19                |                                 | ID1190 (TA577)    | Brentuximab vedotin                         | Lymphoma                                    | 11  | 21  | 42  | 8   | 55        | 7     | 0  |
| 28/03/19                | 22/07/19                        | ID1175 (TA578)    | Durvalumab                                  | Lung cancer                                 | 4   | 4   | 45  | 1   | 0         | 1     | 0  |
| 28/03/19                |                                 | 3911              | Ataluren                                    | Muscular dystrophy                          | 12  | 14  | 35  | 12  | 48        | 34    | 0  |
| 28/03/19                |                                 | 1514              | Dasatinib                                   | Leukaemia                                   | 12  | 14  | 35  | 12  | 48        | 34    | 0  |
| 02/04/19                | 30/05/19                        | ID1339 (TA579)    | Abemaciclib                                 | Breast cancer                               | 0   | 27  | 35  | 21  | 20        | 29    | 0  |
| 05/04/19                | 05/04/19                        | ID1182 (TA581)    | Nivolumab                                   | Renal cancer                                | 4   | 6   | 27  | 4   | 41        | 26    | 0  |
| 05/04/19                | 05/04/19                        | ID1182 (TA581)    | Ipilimumab                                  | Renal cancer                                | 4   | 6   | 27  | 4   | 41        | 26    | 0  |
| 12/04/19                |                                 | 3769              | Blinatumomab                                | Leukaemia                                   | 5   | 20  | 55  | 25  | 34        | 19    | 0  |
| 12/04/19                |                                 | 3750              | Mepolizumab                                 | Asthma                                      | 3   | 20  | 55  | 25  | 34        | 19    | 0  |
| 16/04/19                |                                 | ID1242 (HST9)     | Inotersen                                   | Amyloidosis                                 | 10  | 23  | 51  | 21  | 30        | 15    | 0  |
| 02/05/19                |                                 | ID1210 (TA584)    | Atezolizumab                                | Lung cancer                                 | 6   | 7   | 35  | 5   | 14        | 14    | 0  |
| 09/05/19                | 12/07/19                        | ID938 (TA585)     | Ocrelizumab                                 | Multiple sclerosis                          | 3   | 11  | 118 | 11  | 0         | 11    | 24 |
| 17/05/19                |                                 | ID474 (TA587)     | Lenalidomide                                | Multiple myeloma                            | -   | 7   | 7   | -   | 33        | 21    | 0  |
| 17/05/19                |                                 | ID667 (TA586)     | Lenalidomide                                | Multiple myeloma                            | -   | 7   | 7   | -   | 33        | 21    | 0  |
| 30/05/19                |                                 | ID1153 (TA591)    | Letermovir                                  | Cytomegalovirus                             | 1   | 4   | 35  | 4   | 20        | 8     | 0  |
| 06/06/19                |                                 | ID1160 (TA583)    | Ertugliflozin                               | Diabetes                                    | 0   | 1   | 56  | 1   | 13        | 1     | -  |
| 11/06/19                |                                 | 2777              | Fingolimod                                  | Multiple sclerosis                          | 3   | 15  | 51  | 9   | 8         | 17    | -  |
| 20/06/19                |                                 | ID1039 (TA590)    | Fluocinolone acetonide intravitreal implant | Uveitis                                     | 0   | 8   | 42  | 5   | 60        | 8     | -  |
| 25/06/19                |                                 | 991               | Rufinamide                                  | Epilepsy                                    | 7   | 3   | -   | -   | 59        | 3     | 0  |
| 25/06/19                |                                 | 1214              | Eslicarbazepine acetate                     | Epilepsy                                    | 7   | 3   | -   | -   | 59        | 3     | 0  |
| 02/07/19                | 01/08/19                        | ID1367 (TA592)    | Cemiplimab                                  | Skin cancer                                 | 15  | 15  | 35  | 19  | 1         | 26    | 0  |
| 03/07/19                | 03/07/19                        | ID1069 (TA588)    | Nusinersen                                  | Spinal muscular atrophy                     | 5   | 8   | 29  | 0   | 30        | 20    | 0  |
| 05/07/19                |                                 | ID1346 (TA595)    | Dacomitinib                                 | Lung cancer                                 | 19  | 20  | 27  | 21  | 28        | 33    | 0  |
| 08/07/19                |                                 | ID1279 (HST10)    | Patisiran                                   | Amyloidosis                                 | 16  | 17  | 59  | 18  | 25        | 30    | 0  |

| Appraisal Approval Date | CAA Available Date* | AWMSG or NICE ref | Medicine Name                           | Abbreviated Indication                       | Health Board formulary status ^# |     |     |     |           |       |     |
|-------------------------|---------------------|-------------------|---|--|----------------------------------|-----|-----|-----|-----------|-------|-----|
|                         |                     |                   |   |  | Aneurin Bevan                    | BCU | C&V | CTM | Hywel Dda | Powys | SB  |
| 12/07/19                |                     | ID1478 (TA597)    | Dapagliflozin                           | Diabetes                                     | 3                                | 11  | 55  | 11  | 59        | 11    | 0   |
| 12/07/19                |                     | ID1398 (TA596)    | Risankizumab                            | Psoriasis                                    | 12                               | 13  | 55  | 14  | 59        | 26    | 0   |
| 15/07/19                |                     | ID1036 (TA589)    | Blinatumomab                            | Leukaemia                                    | 0                                | 8   | 52  | 8   | 57        | 8     | 0   |
| 17/07/19                | 30/08/19            | ID1318 (TA593)    | Ribociclib                              | Breast cancer                                | 7                                | 3   | 34  | 0   | 27        | 14    | 0   |
| 26/07/19                | 21/11/19            | ID1124 (TA598)    | Olaparib                                | Ovarian, fallopian tube or peritoneal cancer | 26                               | 7   | 40  | 6   | 8         | 13    | 0   |
| 26/07/19                |                     | ID1293 (TA599)    | Sodium zirconium cyclosilicate          | Hyperkalaemia                                | 0                                | 19  | 41  | 10  | 55        | 12    | -   |
| 31/07/19                |                     | ID1397 (TA607)    | Rivaroxaban                             | Atherothrombotic events                      | 0                                | 82  | 36  | -   | 57        | 7     | -   |
| 08/08/19                | 19/09/19            | ID1306 (TA600)    | Pembrolizumab                           | Lung cancer                                  | 34                               | 41  | 49  | 47  | 0         | 57    | 0   |
| 04/09/19                |                     | ID1054 (HST11)    | Voretigene neparovvec                   | Inherited retinal dystrophies                | 118                              | 28  | 29  | 5   | 22        | 48    | 118 |
| 05/09/19                |                     | ID1150 (TA605)    | Clostridium botulinum neurotoxin type A | Chronic sialorrhoea                          | 12                               | 27  | 28  | -   | 57        | 60    | 0   |
| 16/09/19                |                     | 3977              | Buprenorphine                           | Opioid dependence                            | 2                                | 16  | 52  | 14  | 0         | 17    | 0   |
| 18/09/19                |                     | ID1268 (TA606)    | Lanadelumab                             | Hereditary angioedema                        | 0                                | 14  | 50  | 12  | 8         | 15    | 36  |
| 10/10/19                |                     | ID1364 (TA610)    | Pentosan polysulfate sodium             | Bladder pain syndrome                        | 0                                | -   | 56  | 1   | 13        | 15    | -   |
| 17/10/19                |                     | ID981 (TA612)     | Neratinib                               | Breast cancer                                | 33                               | 13  | 49  | 7   | 7         | 8     | 0   |
| 23/10/19                |                     | 4130              | Zanamivir                               | Influenza                                    | 8                                | 7   | 43  | 1   | 9         | 2     | 0   |
| 23/10/19                |                     | 3917              | Glecaprevir/pibrentasvir                | Hepatitis C                                  | 8                                | 7   | 43  | 1   | 9         | 2     | 0   |

\* Time to formulary addition from appraisal approval date should be within two months for AWMSG Health Technology Appraisals (including the orphan and ultra-orphan appraisal process), NICE Health Technology Appraisals and HSTs and cancer drugs. For NICE recommendations these should be following the first publication of the FAD or the FED for HSTs, and for AWMSG approvals following Welsh Government ratification.

^ Number of days from latest AWMSG/NICE approval statements and formulary status are data submitted by health board/trust. Where no number is provided this can generally be assumed to indicate that the medicine is "already on formulary" but for a different indication. However this is not always the case.

# The determination of formulary status is considered as the availability of the medicine to treat patients.

‡ CAA (Commercial Access Agreement) available date information is provided by the all Wales Medicines Procurement Specialist Pharmacist





|     |  |  |
|-----|--|--|
| Key |  | On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[']' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval. |
|     |  | On formulary. However the number of days stated is outside of the 60 day timescale.  |
|     |  | Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.  |
|     |  | Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.   |

**Table 2. Velindre Cancer Centre medicines status**

| Appraisal Approval Date | CAA Available Date | AWMSG or NICE ref | Medicine name | Abbreviated indication                       | Health Board formulary status |        |     |     |               |          |
|-------------------------|--------------------|-------------------|---------------|--|-------------------------------|--------|-----|-----|---------------|----------|
|                         |                    |                   |               |  | C&V                           | Powys* | SB* | CTM | Aneurin Bevan | VCC ONLY |
| 17/01/19                |                    | ID1227 (TA563)    | Abemaciclib   | Breast cancer                                | 41                            | 41     | 41  | 41  | 41            | 41       |
| 18/01/19                |                    | ID923 (TA562)     | Encorafenib   | Melanoma                                     | 40                            | 40     | 40  | 40  | 40            | 40       |
| 18/01/19                |                    | ID923 (TA562)     | Binimetinib   | Melanoma                                     | 40                            | 40     | 40  | 40  | 40            | 40       |
| 15/02/19                |                    | ID1192 (TA569)    | Pertuzumab    | Breast cancer                                | 44                            | 44     | 44  | 44  | 44            | 44       |
| 15/02/19                |                    | ID1328 (TA571)    | Brigatinib    | Lung cancer                                  | **                            | 44     | 12  | 12  | 12            | 12       |
| 28/03/19                | 22/07/19           | ID1175 (TA578)    | Durvalumab    | Lung cancer                                  | **                            | 0      | 0   | 0   | 0             | 0        |
| 02/04/19                | 30/05/19           | ID1339 (TA579)    | Abemaciclib   | Breast cancer                                | 0                             | 0      | 0   | 0   | 0             | 0        |
| 05/04/19                | 05/04/19           | ID1182 (TA581)    | Nivolumab     | Renal cancer                                 | 17                            | 17     | 17  | 17  | 17            | 17       |
| 05/04/19                | 05/04/19           | ID1182 (TA581)    | Ipilimumab    | Renal cancer                                 | 17                            | 17     | 17  | 17  | 17            | 17       |
| 02/05/19                |                    | ID1210 (TA584)    | Atezolizumab  | Lung cancer                                  | **                            | 47     | 47  | 47  | 47            | 47       |
| 02/07/19                | 01/08/19           | ID1367 (TA592)    | Cemiplimab    | Skin cancer                                  | 20                            | 20     | 20  | 20  | 20            | 20       |
| 05/07/19                |                    | ID1346 (TA595)    | Dacomitinib   | Lung cancer                                  | 47                            | 47     | 47  | 47  | 47            | 47       |
| 17/07/19                | 30/08/19           | ID1318 (TA593)    | Ribociclib    | Breast cancer                                | 0                             | 0      | 0   | 0   | 0             | 0        |
| 26/07/19                | 21/11/19           | ID1124 (TA598)    | Olaparib      | Ovarian, fallopian tube or peritoneal cancer | 26                            | 26     | 26  | 26  | 26            | 26       |
| 08/08/19                | 19/09/19           | ID1306 (TA600)    | Pembrolizumab | Lung cancer                                  | **                            | 34     | 34  | 34  | 34            | 34       |
| 17/10/19                |                    | ID981 (TA612)     | Neratinib     | Breast cancer                                | 33                            | 33     | 33  | 33  | 33            | 33       |

\*Powys and Swansea Bay also commission cancer services from other cancer providers. These dates relate to the Powys and Swansea Bay populations that Velindre Cancer Centre are commissioned for and there may be variability with dates from other cancer service providers.

\*\* Cardiff and Vale have their own lung service.

|            |   |  |
|------------|---|--|
| <b>Key</b> |  | On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[ ]' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval. |
|            |  | On formulary. However the number of days stated is outside of the 60 day timescale.  |
|            |  | Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.  |
|            |  | Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.   |